2024-09-19 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of pharmaceuticals, medical devices, nutrition products, and diagnostics.

**Performance Analysis:**

**1. Return Performance:**

* **Cumulative Return:** 111.03%
* **S&P 500 (VOO) Cumulative Return:** 129.06%
* **Return Gap:** -18.03% (Relative Gap: 22.03%) 

Currently, ABT has underperformed the S&P 500 by 18.03% over the period analyzed. This indicates that while ABT has shown positive growth, its performance lags behind the broader market.

**2. Recent Price Movement:**

* **Closing Price:** $117.59
* **5-day Moving Average:** $117.01
* **20-day Moving Average:** $114.31
* **60-day Moving Average:** $108.68

The current price is slightly above its 5-day moving average, suggesting short-term momentum. However, the price is significantly higher than both its 20-day and 60-day moving averages, indicating potential overbought conditions.

**3. Technical Indicators:**

* **RSI:** 71.9 (Overbought)
* **PPO:** 0.09 (Positive)
* **Delta_Previous_Relative_Divergence:** 7.43 (Short-term upward trend)
* **Expected Return:** 64.08% (Potential 5-year maximum expected return)

The high RSI suggests that the stock is overbought and may be due for a correction. However, the positive PPO and short-term upward trend indicate that the stock has potential for further growth. The expected return suggests a potentially attractive investment opportunity with a high potential for growth.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue | 
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

The most recent earnings report for Q2 2024 revealed that ABT beat earnings expectations with EPS of $0.74, exceeding analyst estimates. However, revenue came in slightly below expectations. Despite a slight miss on revenue, the strong earnings performance indicates positive momentum for the company.

**5. Overall Analysis:**

ABT has shown consistent growth, but its performance has lagged behind the broader market. The stock is currently overbought based on the RSI, but positive momentum from recent earnings and technical indicators suggests potential for further growth. The high expected return makes ABT a potentially attractive investment opportunity, especially for long-term investors.

**6. Conclusion:**

Overall, ABT appears to be a solid company with a strong track record and positive future prospects. While the stock is currently overbought, its strong earnings performance and positive technical indicators suggest potential for continued growth. However, investors should remain cautious due to the high RSI and consider waiting for a potential pullback before investing. 
